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Abstract
Introduction: The aim of the study was to evaluate the endothelioprotective activity of 4-hydroxy-3,5-di-tret-butylcin-
namic acid in conditions of experimental cerebral ischemia.
Materials and methods: The brain ischemia was reproduced by the method of irreversible right-sided thermocoagula-
tion of the middle cerebral artery. As comparative drugs, mexidol (30 mg/kg) and sulodexide (30 U/kg) were used. The 
vasodilating function of the vascular endothelium was assessed by the change in the rate of cerebral blood flow when 
the synthesis of nitric oxide was modified. Antithrombotic function was assessed by changes in the concentration of 
thromboxane A2, fibrinogen, von Willebrand factor activity and platelet aggregation activity. Serum concentration of 
C-reactive protein served as a marker of the state of anti-inflammatory endothelial function. To determine the potential 
mechanism of endothelioprotective activity of 4-4-hydroxy-3,5-di-tret-butylcinnamic acid, the anti-radical activity of 
this compound toward superoxide and nitrosy-radicals was assessed; and the effect of the compound on the mitochon-
drial function was studied, by evaluating the functional activity of mitochondrial ATP synthetase and cytochrome-c-ox-
idase by ELISA.
Results and discussion: In the course of the study, a positive effect of 4-hydroxy-3,5-di-tret-butylcinnamic acid on the 
state of endothelial function in cerebral ischemia was established, which was expressed in the preservation of vaso-
dilating (restoring the vascular reaction to acetylcholine, nitro-L-arginine methyl ether, L-arginine), antithrombotic (a 
decrease in the concentration of thromboxane A2, fibrinogen and von Willebrand factor activity by 241.9% (p <0.05), 
73.5% (p <0.05), 20.4% (p <0.05), respectively, a decrease in the degree of aggregation and platelet aggregation rate by 
56.7 % (p <0.05) and 52.8% (p <0.05), respectively, and anti-inflammatory vascular endothelial function (99.1% C-re-
active protein reduction (p <0.05)). The 4-hydroxy-3,5-di-tret-butylcinnamic acid compound in vitro tests suppressed 
generation of superoxide (IC50 = 1.99 mg/ml) and nitrosyl radical (IC50 = 1.92 mg/ml), eliminated NO-synthase un-
coupling, and restored the mitochondrial function (increase in mitochondrial ATP synthase and cytochrome-c-oxidase 
activity by 23.5% (p <0.05) and 110.8% (p <0.05), respectively).
Conclusion: The study demonstrated the presence of endotheliotropic activity of 4-hydroxy-3,5-di-tret-butylcinnamic 
acid, which is expressed in the preservation of vasodilating, antithrombotic and anti-inflammatory functions of the vas-
cular endothelium in conditions of cerebral ischemia. At the same time, the anti-radical properties of this compound, as 
well as the direct effect on the functional activity of the NO-synthase system and the improvement of the mitochondrial 
function, may underlie the endotheliotropic effects of 4-hydroxy-3,5-di-tret-butylcinnamic acid.
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Introduction
Ischemic stroke is one of the leading causes of death and 
primary disability of the population. The statistical data 
of the World Health Organization show a steady increase 
in the number of cases of ischemic stroke, which annually 
accounts for 15 million registered facts of cerebral circu-
lation disorders. The mortality rate also remains high: out 
of 15 million victims, 5 million die, 5 million get disab-
led, with loss of labor and social adaptation. In addition, 
the number of cases of ischemic stroke is projected to in-
crease to 61 million by 2020. http://www.who.int/cardio-
vascular_diseases/resources/atlas/en.
Currently, the leading method of therapy for ischemic 
stroke is intravenous injection of thrombolytic agents 
(recombinant TPA, streptokinase) or endovascular in-
tervention. However, despite the high efficiency of the 
measures taken, the desired result is often impossible to 
achieve, due to a small “therapeutic window” (less than 
6 hours), the mismatch between the patients and the se-
lection criteria, etc. (Jauch et al. 2013). Thus, the major-
ity of patients exposed to ischemic stroke do not receive 
proper treatment, which dictates the need to search for 
new pharmacotherapeutic approaches to the therapy of 
this emergency condition (Yang et al. 2018). Recent ad-
vances in experimental and clinical angioneurology have 
significantly expanded the range of knowledge of the 
pathogenesis of ischemic stroke. In addition to the clas-
sic elements of the “ischemic cascade” of brain damage, 
which include: decreased energy production, acidosis, 
damage to the BBB with development of edema and local 
inflammation, glutamate calcium excitotoxicity, oxidative 
stress, cytokine cytotoxicity (Woodruff et al. 2011), some 
authors distinguish a relatively new link in the series of 
brain destruction reactions, which is endothelial dysfunc-
tion (Poggesi et al. 2016, Terpolilli et Al. 2012, Chen et al. 
2012). As a labile structure of the vascular endothelium, it 
is constantly exposed to adverse factors: oxidative stress, 
estrogen deficiency, smoking, hyperhomocysteinemia, 
increased shear stress, hyperglycemia, etc. (Favero et al. 
2014). Damage to the endothelial lining leads to failure of 
endothelium-mediated regulation of vascular tone, inten-
sification of vasoconstriction, coagulation, inflammation 
and proliferation. The above mentioned changes create 
conditions for the secondary intensification of cellular 
damage: the permeability of the BBB increases, the cal-
cium conductivity and acidosis increase, and the vasogen 
edema develops (Hu et al. 2017). Thus, damage to the 
vascular endothelium can be both a primary determinant 
of neuronal destruction, and a secondary damaging mech-
anism. Endothelial dysfunction is primarily associated 
with deficiency of NO – a key metabolite mediating all 
endothelial functions: vasodilating, antithrombotic, an-
ti-inflammatory and antiproliferative (Esper et al. 2006). 
Reduction of the total NO can be caused by several mech-
anisms: disconnection of the NO synthase system with a 
decrease in the production of nitric oxide; intensification 
of biodegradation of NO in reaction with active forms of 
oxygen (ROS) with the formation of peroxonitrite (Radi 
2013). A decrease in the activity of the NO-producing 
system developes for a number of reasons: a genetically 
determined defect, a lack of NOS substrate – L-arginine 
and co-enzymes tetrahydrobiopterin and NADPH, excess 
accumulation of ADMA, inactivation by ROS (Chen et 
al. 2013). Biodegradation of NO mainly occurs through 
its interaction with superoxide radical with the formation 
of cytotoxic peroxonitrite as a reaction product. ROS and 
superoxide radicals in particular are formed as products 
of reactions in the mitochondrial respiratory chain, which, 
without their proper inactivation by enzymes of endog-
enous antioxidant system, leads to the development of 
oxidative stress and an increase in the alteration of cells, 
including endotheliocytes, by the type of LPO (Kluge et 
al. 2013). Thus, one of the possible methods of pharma-
cotherapeutic correction of ischemic stroke may be en-
dothelial targeting. To correct the endothelial dysfunction 
arising in conditions of cerebral circulation insufficiency, 
a relatively new pharmacotherapeutic group – endotheli-
oprotective agents, including β-blockers, statins, inhibi-
tors of phosphodiesterase 5, ivabradine – can be used. (Su 
2015). However, the existing spectrum of endotheliotro-
pic substances is limited, and there is practically no means 
with proven endothelioprotective activity (Radenković et 
al. 2013), which in turn dictates a new direction in the 
targeted search for pharmacologically active substances – 
endothelioprotective agents.
The aim of the study: to evaluate the endotheliopro-
tective activity of 4 4-hydroxy-3,5-di-tret-butylcinnamic 
acid under conditions of experimental cerebral ischemia.
Materials and methods
Animals 
The study was performed on 200 male rats of the Wistar 
line. The animals were obtained from the vivarium of 
the Pyatigorsk Medical and Pharmaceutical Institute, a 
branch of the Volgograd State Medical University of the 
Ministry of Health of the Russian Federation, and kept in 
standard conditions (ambient temperature 22±2°C, rela-
tive humidity 65±5%, with natural change of light-dark 
cycle). The care, and all manipulations with animals, met 
the requirements of the European Convention for the Pro-
tection of Vertebrates Used for Experimental and Other 
Scientific Purposes (Strasbourg, 22 June 1998).
Cerebral ischemia model (irreversible occlusion of the 
middle cerebral artery)
In rats, which were narcotized with chloral hydrate (350 
mg/kg), a section of 2 cm2 was sheared to the right and 
below the eye. Then an incision on the skin was made. 
Muscles were separated and the process of the malar bone 
was removed. Using a specially designed bur, a trepa-
nation aperture was drilled above the intersection of the 
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middle cerebral artery with the olfactory tract (Fig. 1). Fu-
rther, coagulation was performed by burning the middle 
cerebral artery under the site of its intersection with the 
olfactory tract. Soft tissues were reconstructed, bone frag-
ments were repositioned. The wound was treated with a 
5% iodine solution. Before awakening, the animals were 
left under a warming lamp. In the postoperative period, 
the animals were transferred to a soft-fodder diet (Beder-
son et al. 1986).
Test-compound, formation of experimental groups. 
Design of the experiment
The investigated object was 4-hydroxy-3,5-di-tret-butyl-
cinnamic acid (ATACL) in a dose of 100 mg/kg. As com-
parative drugs, sulodexide (Alfa Wasserman, Italy) was 
used in a dose of 30 U/kg and mexidol (PHARMASOFT, 
Russia) in a dose of 30 mg/kg. The test compound and 
comparative preparations were administered as a fine 
aqueous suspension per os, daily (one time per day) for 3 
days from the time of the operation. The study was divided 
into 4 test blocks (Fig. 2), in each of which 5 experimental 
groups of animals (n = 10), randomized by age and weight 
(viripotent, weighing 200-220 grams) were formed: pseu-
do-operated rats (PO), to which all sequential manipulati-
ons were applied, with the exception of coagulation of 
the middle cerebral artery; a group of negative control 
animals (NC), with ischemia, but lacking pharmacologi-
cal support; and groups of rats with ischemia receiving 
the test compound and comparative drugs. At the first, 
second and third stages of the experimental work, the 
effect of the test compound on the state of vasodilating, 
antithrombotic, anti-inflammatory vascular endothelial 
functions under conditions of cerebral ischemia, respec-
tively, was assessed; at the fourth stage, possible aspects 
of the endotheliotropic effect of the studied compound 
were evaluated with an assessment of the change in the 
function of the NO-producing system, the anti-radical 
activity of the object under study (in vitro), and the func-
tional activity of the mitochondria.
Evaluation of vasodilating function 
Evaluation of the vasodilating function of the cerebral 
vascular endothelium was performed using the Doppler 
method – recording the average systolic velocity (ASV) 
in the projection of the right medial cerebral artery in 
the modification of the synthesis of endogenous nitric 
oxide. The average systolic velocity was recorded with 
an ultrasound dopplerograph, a USOP-010-01 sensor 
with an operating frequency of 25 MHz, and a working 
computer program MM-D-K-Minimax Doppler v.1.7. 
(Saint-Petersburg, Russia). The modification of the re-
lease of endogenous NO was carried out by intravenous 
administration of test systems: acetylcholine (ACH) 0.1 
mg/kg (Sigma-Aldrich), L-arginine 150 mg/kg (Panre-
ac), nitro-L-arginine methyl ester (L-NAME ) 15 mg/
kg (Sigma-Aldrich). To assess endothelium-independent 
vasodilation, nitroglycerin (NTG, Biomed, Russia) was 
administered in a dose of 0.007 mg/kg. After carrying out 
all the necessary studies, the animals were removed from 
the experiment by instantaneous decapitation, before they 
recovered from anesthesia (Voronkov et al. 2015).
Evaluation of antithrombotic function 
Antithrombotic function of the vascular endothelium was 
assessed by changes in platelet aggregation activity, con-
centration of thromboxane A2, von Willebrand factor and 
fibrinogen.
The analysis of aggregation activity of platelets was 
carried out on a two-channel laser analyzer of platelet 
aggregation ALAT-2 “BIOLA” (SMF “BIOLA”, Russia), 
using the method of determining the relative average size 
of aggregates. When the experiment was set up, 0.3 ml 
of blood serum was put into the cuvette of the agglom-
erate, and incubated at 37°C for 3 minutes. After incu-
bation, aggregation inducers were added: disodium ade-
nosine-5-diphosphate (ADP, SMU “Renam”) in the final 
concentration of 5 μM. The platelet aggregation process 
was recorded for five minutes. The degree and rate of ag-
gregation of the blood platelets was determined from the 
aggregatograms obtained (Gabbasov et al. 1989).
Figure 1. Schematic representation of coagulation of the middle 
cerebral artery.
Figure 2. Design of the experiment.
Note: PO – pseudo-operated animals; NC – negative control 
group of animals; ATACL – 4-hydroxy-3,5-di-tret-butylcinnam-
ic acid compound
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The concentration of fibrinogen was determined by the 
chronometric method on the analyzer of the hemostasis 
parameters of APG2-01 “MINILAB 701”. During the 
test, standard reagent kits of SMU “Renam” were used. 
Lyophilized reagents were stored, meeting the conditons 
of temperature and prepared ex tempore. The progress of 
the analysis was strictly consistent with the instructions 
given in the kit.
The activity of von Willebrand factor (FW) was de-
termined by the agglutination method. To the diluted 
imidazole buffer (1:5) plasma (50 μl) 50 μl Willebrand 
reagent was added. In transmitted light against a dark 
background, with a continuous rocking of the slide, the 
time was recorded from the addition of the Willebrand 
reagent until agglutination appeared and the FW activity 
in % was determined from the calibration plot.
The concentration of thromboxane A2 was determined 
by solid-phase immunoassay. The work used species-spe-
cific sets of reagents produced by Cloud Clone corp. The 
object for the study was serum, obtained according to the 
instructions attached to the kit. The progress of the anal-
ysis was in accordance with the recommendations of the 
manufacturer of the kit. The results were read on an In-
finite F 50 micro plate reader (Tecan, Austria).
Evaluation of the anti-inflammatory function 
The anti-inflammatory function of the vascular endothe-
lium was assessed by the change in the concentration of 
the C-reactive protein. The content of C-reactive protein 
(CRP) in the blood serum was measured by the latex-ag-
glutination method using a standard set of reagents produ-
ced by the company “Arbis +”.
Evaluation of potentially possible aspects of the 
mechanism of endotheliotropic action of 4-hy-
droxy-3,5-di-tret-butylcinnamic acid
The activity of the NO synthase system and the mitochond-
rial function was evaluated by a change in the concentra-
tion of NOS isoenzymes (eNOS, iNOS, nNOS), cytochro-
me-c-oxidase (COX), and mitochondrial ATP synthetase 
in rat brain ultracentrifugate. The work used species-spe-
cific sets of reagents produced by Cloud Clone corp. The 
sample preparation and the course of the analysis were in 
accordance with the instruction attached to the kit.
The antiradical activity of the compound studied was 
evaluated by the ability to suppress superoxide and ni-
trosyl radicals in the model medium.
Superoxide radical – antiradical activity
The analysis was carried out according to the method of 
Winterbourn (Winterbourn et al. 1975). The superoxide 
radical was generated in the phototreatment reaction of 
riboflavin. The incubation medium consisted of 0.1 ml of 
the solution of the test compound and comparative drugs 
in various concentrations (10 mg/ml, 5 mg/ml, 2.5 mg/ml, 
1.25 mg/ml) + 0.1 ml of a 1.5 mM solution of nitro-blue 
tetrazolium + 0.2 ml of 0.1 M solution of EDTA + 0.05 
ml of 0.12 mM riboflavin solution + 2.55 ml phosphate 
buffer (pH 7.4). The resulting mixture was incubated for 
5 minutes at 25°C. The absorbance of the samples was 
measured at 560 nm against air. Positive control was the 
incubation medium without addition of the estimated so-
lutions. The percentage of inhibition was calculated by 
the formula (1):
% inhibition = Ax / A0 * 100, (1) where
Ax – absorbance of the sample;
A0 – absorbance of the positive control sample
Nitrosyl radical – antiradical activity
The course of the analysis corresponded to the method 
described by Marcocci (Marcocci et al. 1994): 2 ml of 10 
mM sodium nitroprusside + 0.5 phosphate buffer solution 
(pH 7.4) + 0.5 ml of the solution of the test compound and 
comparative drugs were added to the cuvette. The resul-
ting mixture was incubated at 25°C for 15 minutes. After a 
period of incubation, 0.5 ml of Griss reagent was added to 
the medium, incubated for 30 minutes at room tempera-
ture. The absorbance of the samples was measured at 546 
nm. The percentage of inhibition of the nitrosyl radical 
was calculated according to the formula (2):
% inhibition = Ax / A0 * 100, (2) where
Ax – absorbance of the sample before the addition of 
the Griss reagent;
A0 – absorbance of the sample after the addition of the 
Griss reagent.
Statistical analysis
The results of the experiments were processed using the 
variational statistics method using the STATISTICA 6.0 
software package (StatSoft, Inc., USA for the Windows 
operating system) and Microsoft Excel 2010. The average 
value and the standard error of the mean value were cal-
culated, the data was expressed as M±SD. The obtained 
results were checked for normality by Shapiro-Wilk test. 
In the case of subordination to the laws of normal distri-
bution, the Student’s t-test was used to compare the aver-
ages. Otherwise, further statistical processing of the expe-
rimental results was carried out using the nonparametric 
Mann-Whitney U-test. The IC50 value was calculated by 
the probit analysis method.
Results
Evaluation of vasodilating function of vascular endot-
helium in the presence of cerebral ischaemia
In pseudo-operated rats, when administering ASH, ASV 
increased by 48.7% (p <0.01) (Table 1) from its initial va-
5lue in this group of animals. The introduction of L-arginine 
did not cause significant changes in cerebral hemodyna-
mics in PO animals. At the same time, on the background 
of the blockade of enzyme systems for NO synthesis, by 
intravenous injection of nitro-L-arginine methyl ester, the 
rate of cerebral blood flow in PO animals decreased by 
23.1% (p <0.05) Evaluating the endothelium-independent 
vasodilation in animals of the PO groups there was an 
increase in ASV with nitroglycerin, relative to the back-
ground blood flow velocity, by 54.6% (p <0.01).
In the NC group of rats, development of endothelial 
dysfunction with violation of NO-synthesizing system ac-
tivity and failure of endothelium-mediated regulation of 
vascular tone were detected. This fact is confirmed by a 
small, in comparison with PO rats, insignificant response 
to intravenous administration of ACH and L-NAME. 
Thus, in the NC group of animals, an increase in (ACH) 
ASV and its decrease (L-NAME) from the baseline lev-
el was 12% and 11.4% (Table 1), respectively, which is 
305.8% (p <0.05) and 102.6% (p <0.05) less that these 
figues in PO rats. In response to the introduction of L-ar-
ginine in NC rats, the rate of cerebral blood flow increased 
from its original level by 33.1% (p <0.05), which in turn 
indicates that in this group of rats the development of the 
“L-arginin paradox” phenomenon. The introduction of ni-
troglycerin caused an increase in ASV (from its baseline 
level) in the group of NC rats by 55.9% (p <0.01), which 
did not differ statistically significantly from the indices of 
the PO group of animals.
In animals receiving sulodexide, with the introduction 
of acetylcholine, ASV increased by 25.6% (p<0.05) from 
its baseline level. With the introduction of L-arginine to 
this group of rats, the rate of cerebral blood flow increased 
(in comparison with the initial value) by 18.3%, which 
was statistically significantly 80.9% (p <0.05) less than 
that of the group of animals. Against the background of 
L-NAME in rats receiving sulodexide, the ASV decreased 
by 23.1% (p<0.05) (Table 1). Intravenous administration 
of NTG promoted an increase in the rate of local cerebral 
blood flow by 52.3% (p <0.01).
When using mexidol, the rate of cerebral blood flow 
in rats in response to the administration of ACH, ASV in-
creases by 21.1% (p <0.05), and L-NAME decreases by 
12.8%. With the intravenous administration of L-arginine 
to rats receiving mexidol, ASV increased from its base-
line by 31.2% (p <0.05). Endothelium-independent vaso-
dilation with the introduction of NTG was not statistically 
significantly different from that in PO rats.
Stimulated with acetylcholine, synthesis of nitric oxide 
caused an increase in the rate of local cerebral blood flow 
by 32.9% (p <0.05) from its initial level in rats receiv-
ing ATACL (Table 1). It should be noted that the vascular 
response to the administration of the ACH with ATACL 
exceeded that of the NC group of animals by 174.2% 
(p <0.05). Under the conditions of administration of the 
NO donor – L-arginine, in the animals of this group ASV 
increased by only 13.8%, which was statistically signifi-
cantly lower than the similar value in the NC group of 
animals by 139.9% (p <0.05). When L-NAME was inject-
ed to rats treated with ATACL, ASV decreased by 17.4% 
from its initial value (p <0.05). Intravenous introduction 
of NTG to this group of animals (Table 1) contributed to 
an increase in ASV, compared with its original value of 
51.1% (p<0.01).
Evaluation of antithrombotic function 
The degree and rate of platelet aggregation in the PO 
group of animals were 1.536±0.129 RU, and 0,993±0,169 
RU. (Table 2), respectively. As a result of focal cerebral 
ischemia, an increase in the degree of platelet aggregation 
by 70% (p <0.05) and speed by 195.8% (p <0.02) was 
detected in the NC group of rats. The introduction of su-
lodexide and mexidol virtually balanced the decrease in 
the degree and rate of platelet aggregation. When using 
sulodexide, the degree of aggregation of thrombocytes in 
the NC group of animals decreased by 41.9% (p <0.05), 
and with administration of mexidol it decreased by 44.8% 
(p <0.05). The aggregation rate decreased by 74.7% (p 
<0.05) (sulodexide) and by 65.7% (p <0.05) (mexidol).
With the administration of ATACL compound, the de-
gree of platelet aggregation decreased by 56.7% (p <0.05) 
compared that of NC group of rats, and the rate – by 
52.8% (p <0.05). There were no statistically significant 
differences between the group of animals treated with 
ATACL and comparative drugs (sulodexide and mexidol) 
(Table 2).
In the NC group of animals, an increase in the fibrino-
gen concentration, activity of von Willebrand factor and 
thromboxane A2 concentration was observed compared 
Table 1. Effect of the test compound and comparative drugs on the change in the vasodilating function of the vascular endothelium 
under conditions of cerebral ischemia.
Group ACH L-arginine L-NAME NTG
PO 48.7±1.030* -2.2±0.430 -23.1±1.235∆ 54.6±0.592*
NC 12.0±1.670α 33.1±5.482 ∆ α -11.4±0.669 α 55.9±2.167*
Sulodexide 25.6±1.062 ∆ α 18.3±1.664 αμ -23.1±1.846 ∆ 52.3±1.428*
Mexidol 21.1±2.407 ∆ α 31.2±3.920 ∆ α -12.8±2.805 55.1±1.018*
ATACL 32.9±2.551 ∆μ 13.8±2.256μ -17.4±1.072 ∆ 51.1±0.866*
Note: statistically significant relative to background blood flow velocity (Student’s t-test * – p<0.01; Δ-p <0.05); α – statistically 
significant relative to the P/O group of animals (Student’s t-test, p <0.05); μ – statistically significant relative to the N/C of the group 
of animals (Student’s t-test, p<0.05).
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to the PO group of rats by 247.1% (p <0.05); 45.4% (p 
<0.05) and 301.6% (p <0.05), respectively (Table 2). 
Against the background of the use of sulodexide, a 68% 
(p <0.05) decrease in the concentration of fibrinogen rel-
ative to the NC group of animals was observed, FW ac-
tivity decreased by 23% (p <0.05),and thromboxane A2 
concentration – by 197.7% (p <0, 05). When mexidol was 
used in rats, a decrease in fibrinogen and thromboxane 
A2 concentration by 29.8% (p <0.05) and by 196.1% (p 
<0.05), respectively, was observed in comparison with 
the animals of the NC group. When animals were injected 
with ATACL, the concentration of fibrinogen and throm-
boxane A2 decreased by 73.5% (p <0.05) and 241.9% (p 
<0.05), respectively, compared with the NC group of rats. 
FW activity when using ATACL compound, compared to 
the animals not receiving any pharmacological support, 
decreased by 20.4% (p <0.05).
Evaluation of the anti-inflammatory 
In case of focal cerebral ischemia, a 6.2-fold (p <0.05) 
increase in the concentration of CRP in the blood serum 
was observed in animals, compared with the PO group of 
rats (Table 3).
When mexidol was used, the content of C-reactive pro-
tein (Table 3) in rats decreased by 65.5% (p <0.05) com-
pared with the NC group of animals.
In rats treated with sulodexide and ATACL, the con-
centration of the C-reactive protein (Table 3) in compari-
son with the NC group of animals decreased by 86.3% (p 
<0.05) and 99.1% (p <0.05), respectively.
Evaluation of the potential mechanisms of endothe-
liotropic activity of 4-hydroxy-3,5-di-tret-butylcinna-
mic acid
In case of focal cerebral ischemia, rats showed inhibition 
of endothelial NO synthase (the concentration of eNOS in 
the NC group of rats decreased by 65.4% (p <0.05) com-
pared with that of the PO group of animals), and an incre-
ase in the concentration of nNOS and iNOS by 63,5% (p 
<0.05), and 30.8% (p <0.05), respectively (Table 4). In 
addition, in the NC group of rats there was a decrease in 
mATP and COX relative to the PO group of animals by 
129.1% (p <0.05) and 130.5% (p <0.05)
When mexidol was used in rats, a decrease in the con-
centration of nNOS and iNOS (by 14.7% and 39.3% (p 
<0.05), respectively) was observed in comparison with 
Table 3. Changes in the concentration of C-reactive protein in rats blood serum in case of focal cerebral ischemia.
Group PO NC Sulodexide Mexidol ATACL
CRP, mg/l 2.23±0.228 13.92±1.125∆ 7.46±0.527* 8.41±0.743* 6.99±0.446*
Note: Δ – statistically significant relative to the PO group of rats (Mann-Whitney U test, p <0.05); * – statistically significant relative 
to the NC group of rats (Mann-Whitney U test, p <0.05).
Table 4. Effect of ATACL compound on the concentration of NOS isozymes and mitochondrial function markers on cerebral isch-
emia in rats.
Group P/O NC Sulodexide Mexidol ATACL
nNOSng/ml 16.7±0.013 27.3±0.045# 23.8±0.012 12±0.011* 17±0.027*
iNOSng/ml 13±0.008 17±0.003# 12.2±0.013* 10.1±0.006* 10.5±0.002*
eNOSpg/ml 77.9±0.088 47.1±0.065# 53.6±0.069 60.7±0.095* 100.9±0.022*
mATPng/ml 125.5±20.894 54.77±6.583# 72.05±8.838* 56.57±2.656 67.66±4.824*
COXng/ml 48.78±0.287 21.16±2.046# 40.25±1.891* 21.24±1.961 44.6±2.235*
Note: # – statistically significant relative to the PO group of animals (Mann-Whitney U test, p <0.05); * – statistically significant 
relative to the NC group of animals (Mann-Whitney U test, p <0.05).
Table 2. Effect of the test compound and comparative drugs on the change of antithrombotic function of the vascular endothelium 
under conditions of cerebral ischemia.
Group Degree of aggregation (relative units)
Rate of aggregation 
(relative units) FW, % Fibrinogen, g/l Thromboxane А2, ng/ml
PO 1.536±0.129 0.993±0.169 93.4±1.077 1.53±0.123 10.95±0.266
NC 2.613±0.382α 2.937±1.056# 135.8±1.2# 5.31±0.408# 43.97±1.236#
Sulodexide 1.842±0.407* 1.681±0.532* 110.4±5.144* 3.16±0.276* 14.77±0.441#
Mexidol 1.805±0.297* 1.772±0.235* 127±3.114 4.09±0.606* 14.85±0.625#
ATACL 1.668±0.148* 1.922±0.098* 112.8±4.841* 3.06±0.51* 12.86±0.124#
Note: α – is statistically significant relative to the PO group of animals (Student’s t-test, p <0.05); # – statistically significant relative 
to the NC group of animals (Mann-Whitney U test, p <0.02); * – statistically significant relative to the NC of the group of animals 
(Student’s t-test, p <0.05).
7the NC group of animals, as well as a slight increase in 
the eNOS concentration by 13.8%. Also in animals when 
administering mexidol in comparison with NC rats, the 
concentration of mATP increased by 31.6% (p <0.05), and 
the COX content increased by 90.2% (p <0.05).
When administering sulodexide (Table 4), in compar-
ison with the NC group animals, an increase in the con-
centration of eNOS was observed (Table 4) by 28.9% (p 
<0.05), accompanied by a decrease in the content of nNOS 
and iNOS by 127.5% (p <0.05) and 68.3% (p <0.05), re-
spectively. The concentration of mATP and COX when 
administering sulodexide, was statistically significantly 
different from that of the NC rat group.
In animals receiving the ATACL compound, the con-
centration of eNOS (compared with the NC group of 
rats) increased by 114.2% (p <0.05), the concentration of 
nNOS and iNOS in this group of animals, by contrast, 
decreased by 60.6% (p <0.05) and 61.9% (p <0.05), re-
spectively. At the same time, the administration of the 
ATACL compound promoted an increase in the content 
of mATP and COX, in comparison with that in the NC 
group of rats, by 23.5% (p <0.05) and 110.8% (p <0.05), 
respectively.
Assessing the antiradical activity (Fig. 3) of the test 
compound, it was found out that 4-hydroxy-3,5-di-tret-bu-
tylcinnamic acid exhibits pronounced “scavenging” prop-
erties with respect to the superoxide and nitrosyl radical. 
Thus, in a concentration of 10 mg/ml, the compound un-
der study inhibited the generation of superoxide radical 
by 78.4% and of nitrosyl radical by 79.6% (Fig. 3), the 
IC50 value being 1.99 mg/ml and 1.92 mg/ml, respective-
ly, which was comparable with the indices of mexidol (IC 
50O2-* = 1.95 mg/ml, IC50NO* = 2.35 mg/ml) and exceeded 
the indices of sulodexide (IC50O2-* = 5.06 mg/ml, IC50NO* = 
6.24 mg/ml).
Discussion 
Endothelium is a monolayer of cells, of mesenchymal ori-
gin, performing a number of functions aimed at maintai-
ning vascular homeostasis (Kim et al. 2012).
Being a highly specific and highly organized system, 
the vascular endothelium is exposed to a number of un-
favorable factors, leading to a violation of its anatomical 
or functional integrity – when endothelial dysfunction de-
velops. In endothelial dysfunction, the endothelium-de-
pendent mechanism of vascular homeostasis is disturbed, 
which contributes to the activation of vasoconstriction, 
platelet activation, oxidative stress, thrombosis, coagula-
tion and inflammation.
Endothelial dysfunction is a universal pathophysiolog-
ical process that underlies many cardiovascular and endo-
crine diseases such as arterial hypertension, atheroscle-
rosis, ischemic stroke, ischemic heart disease, diabetes, 
etc. (Lau et al. 2015). In this connection, correction of 
endothelial dysfunction and the timely administration of 
agents with endothelioprotective activity can be consid-
ered one of the new directions in the pharmacotherapy of 
“vascular” diseases, including cerebrovascular disorders 
(Gimbrone et al. 2016). However, “endothelioprotection” 
in most cases refers to the number of additional (pleio-
tropic) effects of pharmacologically active substances, 
and medications with proven endotheliotropic effects 
currently do not exist (except for sulodexide) (Su 2015). 
Therefore, a targeted search for endothelioprotectors for 
therapy of cerebrovascular disoders is a promising mod-
ern direction of experimental and clinical pharmacology.
In the course of the study, it was found that the use 
of 4-hydroxy-3,5-di-tret-butylcinnamic acid contribut-
ed to the restoration of vasodilating, antithrombotic and 
Figure 3. Antiradical properties of 4-hydroxy-3,5-di-tret-butylcinnamic acid and comparative drugs.
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anti-inflammatory functions of the vascular endothelium 
under conditions of cerebral ischemia. The positive en-
dotheliotropic effect of 4-hydroxy-3,5-di- tret-butylcin-
namic acid is probably associated with the suppression 
of one of the leading pathogenetic mechanisms of endo-
theliocyte damage – oxidative stress. It is known that the 
hyperproduction of free radicals, in particular of the su-
peroxide radical, promotes accelerated biodegradation of 
nitric oxide and has a direct inhibitory effect on eNOS, as 
a result of which the activity of iNOS increases compen-
satorily, with the hyperproduction of NO and the growth 
of the peroxonitrite amount, thereby closing the “vicious 
circle” of endothelial destruction (Kar et al. 2013). The 
study demonstrated that 4-hydroxy-3,5-di-tret-butylcin-
namic acid in vitro exhibits pronounced antiradical activ-
ity against superoxide and nitrosyl radicals. The presence 
of direct antioxidant activity is probably explained by the 
chemical structure of 4-hydroxy-3,5-di- tret-butylcin-
namic acid. The presence of a hydroxyl group in the struc-
ture of the compound increases its reducing properties, 
since it is the mobile proton of the O-H group that is the 
primary center for the binding of the free radical. In ad-
dition, a vinylenic fragment is present in the structure of 
4-hydroxy-3,5-di- tret-butylcinnamic acid, which, under 
the influence of tret-butyl radicals of the aromatic nucle-
us, stabilizes the hydroxycinnamic acid radical to form a 
reactively inactive phenoxyl which terminates the further 
course of free radical reactions (Teixeira et al. 2012).
The positive effect of 4-hydroxy-3,5-di- tret-butyl-
cinnamic acid on the mitochondrial function, expressed 
in the restoration of cytochrome-c-oxidase and mito-
chondrial ATP synthetase activity, was also established 
during the study, which can also underlie the antioxi-
dant properties of 4- hydroxy-3,5-di- tret-butylcinnamic 
acid. It is known that the reaction of the mitochondrial 
respiratory chain is one of the main sources of reactive 
oxygen indermediates in the cell, while from 2% to 5% 
of the consumed oxygen goes to the production of ROS 
(Trinity et al. 2016). Dissociation of the function of cyto-
chrome-c-oxidase leads to a disastrous for the cell growth 
of the amount of ROS, disrupting the further course of the 
reactions of conjugation of oxidation and phosphoryla-
tion, ie, deterioration of the function of the mATP (Cheng 
et al. 2012). The preservation of the optimal function of 
these mitochondrial enzyme complexes under the action 
of 4-hydroxy-3,5-di- tret-butylcinnamic acid provides to 
eliminate the ROS-generating ability of mitochondria. 
In addition, the improvement in mitochondrial function 
contributes to leveling the mitochondrial dependent cas-
cade of apoptosis (Choe et al. 2015) and improving ener-
gy production (Fig. 4) (Errea et al. 2015), which requires, 
however, further study.
Figure 4. Mechanisms of endotheliotropic effects of 4-hydroxy-3,5-di-tret-butylcinnamic acid (ATACL)
Note: BBB – blood-brain barier; ATP – adenosine triphosphate; mATP – mitochondrial ATP-syntase; COX – cytochrome-c-oxidase; 
ROS – reactive oxygen radicals; NOS – nitric oxyde syntase; eNOS – endothelial nitric oxyde syntase; iNOS – inducible nitric 
oxyde syntase; CASP 8 – caspase 8; AIF – apoptosis inducing factor; ENDOG – endonuclease G; ONOO- – peroxonitrite; ATACL 
– 4-hydroxy-3,5-di-tret-butylcinnamic acid compound.
9Conclusion
The study demonstrated that 4-hydroxy-3,5-di-tret-butyl-
cinnamic acid has endothelioprotective activity in condi-
tions of cerebral ischemia comparable to sulodexide and 
mexidol. The use of 4-hydroxy-3,5-di-tret-butylcinnamic 
acid contributed to the preservation of vasodilating, an-
tithrombotic and anti-inflammatory functions of the vas-
cular endothelium under conditions of cerebral ischemia 
in rats. Potential mechanism of endotheliotropic activity 
of 4-hydroxy-3,5-di-tret-butyl cinnamic acid may be its 
having antiradical activity, expressed in the suppression 
of generation of superoxide (IC50 = 1.99 mg/ml) and nitro-
syl radicals (IC50 = 1.92 mg/ml), as well as an improve-
ment in the mitochondrial function.
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